Presentation at BioPartnering Europe Conference, London. October 2010
Upcoming SlideShare
Loading in...5

Presentation at BioPartnering Europe Conference, London. October 2010







Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds



Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

Presentation at BioPartnering Europe Conference, London. October 2010 Presentation at BioPartnering Europe Conference, London. October 2010 Presentation Transcript

  • Advanced Cell TechnologyCorporate PresentationOctober 20101
  • This presentation is intended to present a summary of ACT’s (“ACT”, or “AdvancedCell Technology Inc”, or “the Company”) salient business characteristics.The information herein contains “forward-looking statements” as defined under thefederal securities laws. Actual results could vary materially. Factors that could causeactual results to vary materially are described in our filings with the Securities andExchange Commission.You should pay particular attention to the “risk factors” contained in documents wefile from time to time with the Securities and Exchange Commission. The risksidentified therein, as well as others not identified by the Company, could cause theCompany’s actual results to differ materially from those expressed in any forward-looking statements.Cautionary Statement Concerning Forward-LookingStatements2
  • State of the Company• Phase I/II ESC trial fully-funded (and notaffected by court ruling) and awaiting FDAapproval• “Embryo-safe” cell lines may qualify forfederal funding, despite recent court ruling• Actively pursuing alternatives toaccelerate development of programs3
  • ACT TherapeuticsACT Proprietary HumanTherapeutic ProgramsTreatment Clinical StageBlastomere ProgramDevelopment of embryonic stem cell lines withoutdestruction of embryoPre-ClinicalRetinal Pigment Epithelium(RPE) ProgramTreatment of Age-related Macular Degeneration(AMD) and Retinal Degenerative DiseasesClinical INDawaitingFDA approvalMyoblast ProgramTreatment of Heart Disease, Heart Attack andHeart FailurePhase IIHemangioblast programTreatment of Diseases and Disorders of theBlood, Circulatory and Vascular SystemsPre-Clinical4
  • Single Blastomere Technology• Company scientists successfully generate stem cell lineswithout destruction of embryo• Utilizes PGD extraction of single blastomere• PGD is safe and routine – has been used in thousands ofpregnancies in United States and Europe alone.• Cell lines retain potential to form all cells in the human body.• Resulting human ES cell lines have been demonstrated to bemore robust and reproducible than traditional ICM-derivedlines.• Technology has been reproduced and peer-reviewed onseveral occasions, and is currently being used in preclinicalstudies and a product awaiting FDA approval for IND study.5Blastomere Program:hESCs Without Embryo Harm
  • • Enables Derivation of New hESC Lines via Pre-implantation Genetic Diagnosis (PGD) Method,Preserving Development Potential of the Embryo• Offers source of autologous ES cells for donorduring his/her life, and closely matched allogeneicsource for blood relatives.• 4 hESC lines awaiting NIH approval for funding – embryosfrom which these lines were derived were not destroyed.• Technology is used to develop RPE cells for our clinicaltrials for Juvenile Macular Degeneration. (no FederalFunding)• Technology is used to develop Hemangioblasts –potential source for red blood cells and platelets.HemangioblastsDifferentiated fromBlastomere hESC Lines6Blastomere Program:Proven Alternative hESC Method with added Benefits
  • • The Sherley v Selebius case presents a major challengefor the regenerative medicine sector, without a doubt.• However, ACT has anticipated this development forsome time• ACT has been taking high-level, face-to-face meetings inDC with all the relevant players, in both houses and onboth sides of the aisle, as well as with NIH and HHS.• ACT‟s Single Blastomere technique for isolatinghESC‟s is likely not subject to the language JudgeLamberth used in Preliminary Injunction.• ACT stands ready to make these cells available tothe research community, if approved.7With Crisis, Comes OpportunityCurrent Challenge to hESC Federal Funding
  • Institutional CollaboratorsAdvanced Cell’s Institutional Collaborators include:Casey Eye Institute Mayo ClinicMoran Eye Institute UCSFHarvard Johns HopkinsStanford Sloan KetteringUniversity of Florida University of IowaUniversity of Illinois U.C. BerkeleyColorado State University8
  • Robust Patent Portfolio• RPE Program• Broad protection for production of RPE cells from human ES Cells• Includes two issued US Patents• Cover use of hESC-dervied RPE cells for treatment of retinaldegenerative disorders• Single Blastomere• Pending patent application for key technology• Induced Pluripotency (iPS)• ACT has earliest priority date to use of key regulatory factors required forgenerating iPS cells.• Transdifferentiation• Broad filings directed to transdifferentiation without viral vectors• SCNT• Dominant issued patents• Parthenogenesis• Aquired Infigen patents which are controlling in parthenogenesis9Realizing the fruits of more than adecade of important discoveries….
  • ACT’s RPE Program IND - Status• Received Orphan Indication• Application for IND Being Reviewed10• Initial IND for Stargardt’s Disease• Trial Design Dovetails Into Second IND, for Dry AMD• Represents $25-30 Billion Worldwide Market, With NoEffective Therapies Currently Available
  • Myoblast Program HighlightsTarget Market for Myoblast ProgramSufferers of Heart Failure, Chronic HeartFailure and patients with scarred orischemic (dead) heart tissue caused byor related to heart attackProgram StatusClearance from FDA to Proceed withPhase II Clinical Trials in the U.S.Charlestown, MA GMP Facility11
  • Hemangioblast Program: Partnership• Joint Venture with leading Korean stem celldeveloper CHA Biotech Co.• The J.V., „Stem Cell & Regenerative MedicineInternational‟, is focused on the development ofhuman blood cells and related products12• Developing IND submission for redblood cells and/or platelets derivedfrom iPS cells
  • The Advanced Cell Technology TeamWorld Class Scientific Team Led BySeasoned Management TeamDr. Robert Lanza, M.D. – Chief Scientific OfficerDr. Jonathan Dinsmore, Ph.D. – Myoblast Project AdvisorMatthew Vincent, Ph.D. – Business Development and IP Strategy13William M. Caldwell IV – Chairman & CEOEdmund Mickunas – Vice President of RegulatoryRoger Gay, PhD – Senior Director of ManufacturingRita Parker – Director of OperationsBill Douglass – Director of Corporate Communications & Social Media
  • Thank you for your timeFor more information, visit www.advancedcell.comAdvanced Cell Technology is traded on the OTC BB, symbol: ACTC